Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) vs BIO-TECHNE Corp (TECH) Price & Performance

First Trust NASDAQ Clean Edge Green Energy Idx FdTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

First Trust NASDAQ Clean Edge Green Energy Idx Fd vs BIO-TECHNE Corp — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $49.69 (market cap $575.99M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 19.7× First Trust NASDAQ Clean Edge Green Energy Idx Fd's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while First Trust NASDAQ Clean Edge Green Energy Idx Fd pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ Clean Edge Green Energy Idx Fd for 50 Days and BIO-TECHNE Corp for 63 Days on average.

QCLNTECH
Market Cap
$575.99M$11.37B
Volume
85,8553,153,511
Sector
Sector/ThematicHealth
52-Week High
$68.47$72.61
52-Week Low
$41.10$43.31
Typical Hold Time
50 Days63 Days
Enterprise Value
—$11.40B
Dividend Yield
—0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Trust NASDAQ Clean Edge Green Energy Idx Fd

QCLN trades at $49.44, down 2.62% today but maintains a bullish technical outlook with strong moving average support. The clean energy ETF benefits from geopolitical tensions accelerating renewable energy adoption globally. Recent news highlights increased data center energy demand and political focus on clean energy policies as key growth catalysts.

The ETF's performance remains tied to U.S. political outcomes and federal energy policy, with recent outperformance against major indices. Key risks include policy uncertainty and market volatility, while institutional interest grows amid global energy security concerns and the ongoing energy transition.

BIO-TECHNE Corp

TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.

Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

QCLN
0% Buy100% Sell
Avg holding period · 50 Days
TECH

No sentiment data available yet.

Top news

Latest headlines on both assets

About First Trust NASDAQ Clean Edge Green Energy Idx Fd

QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.

Read more on QCLN →

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH →